A Review of Physical Activity and Circulating miRNA Expression: Implications in Cancer Risk and Progression
Suzanne Dufresne, Amelie Rebillard, Paola Muti, Christine M. Friedenreich, Darren R. Brenner

To cite this version:

HAL Id: hal-01713229
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01713229
Submitted on 28 Feb 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
A review of physical activity and circulating-miRNA expression: Implications in cancer risk and progression

Suzanne Dufresne¹, Amélie Rébillard¹, Paola Muti², Christine M. Friedenreich³,⁴,⁵, Darren R. Brenner³,⁴,⁵

1. Movement, Sport and Health Sciences Laboratory, EA 1274, University Rennes 2, ENS Rennes, Bruz, France.
2. Department of Oncology, McMaster University, Hamilton Ontario, Canada
3. Department of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Calgary, Alberta, Canada
4. Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
5. Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Running title: Physical activity, MiRNA expression and cancer

Key words: microRNAs; c-miRNA; physical activity; exercise; cancer

Abbreviations list:
AGO2: Argonaute2
CCL2: Chemokine ligand 2
C-miRNA: circulating miRNA
CPK: Phosphocreatine Kinase
DNA: DeoxyriboNucleic Acid
EGFR: Epidermal Growth Factor Receptor
ERK: Extracellular signal-Regulated Kinases
FIIT: Frequency, Intensity, Timing and Type
HDL: High Density Lipoprotein
IGF1R: Insulin-like Growth Factor 1 Receptor
LDL: Low Density Lipoprotein
MAPK: Mitogen-Activated Protein Kinases
miRNA: microRNA
mRNA: messenger RNA
MVB: Multi-Vesicular Bodies
PA: Physical Activity
PBMC: Peripheral Blood Mononuclear Cell
PDCD4: Programmed cell death 4
PI3K: PhosphoInositol 3-Kinase
PLC: PhosphoLipase C
PTEN: Phosphatase and tensin homolog
RT-qPCR: real-time quantitative reverse transcription polymerase chain reaction
RNA: RiboNucleic Acid
RNase: ribonuclease
RTK: Receptor Tyrosine-Kinase
STAT3: Signal Transducer and Activator of Transcription 3
TIMP3: Tissue Inhibitor of MetalloProteinases-3
VO$_{2\text{max}}$: maximal oxygen consumption
Financial support:

Suzanne Dufresne was supported by the Ministère de l'Enseignement Supérieur et de la Recherche (France) while writing this review paper.

Dr Darren Brenner is supported by a Capacity Development Award Cancer Prevention Development Career Award from the Canadian Cancer Society (#703917).

Dr Christine Friedenreich is supported by an Alberta Innovates-Health Solutions Health Senior Scholar Award and an Alberta Cancer Foundation Weekend to End Women’s Cancers Breast Cancer Chair.

Dr Paola Muti is supported by the ArcelorMittal Dofasco Chair.

Dr Amélie Rebillard is financed by Ministère de l’Enseignement Supérieur et de la Recherche (France).

Corresponding author

Dr. Darren Brenner
Department of Cancer Epidemiology and Prevention Research
CancerControl Alberta, Alberta Health Services
Holy Cross Centre, Room 513
Box ACB, 2210 2nd Street S.W.
Calgary, Alberta, CANADA T2S 3C3
Tel: (403) 698-8178
Fax: (403) 476-2654
Email: darren.brenner@albertahealthservices.ca
ABSTRACT

The role of circulating microRNAs (c-miRNAs) in carcinogenesis has garnered considerable scientific interest. MiRNAs may contribute actively to cancer development and progression, making them potential targets for cancer prevention and therapy. Lifestyle factors such as physical activity (PA) have been shown to alter c-miRNA expression but the subsequent impact on cancer risk and prognosis is unknown. To provide a better understanding of how PA reduces the risk of cancer incidence and improves patient outcomes, we conducted a review of the impact of PA on c-miRNA expression, which includes a comprehensive synthesis of studies examining the impacts of acute and chronic exercise on expression of c-miRNAs. While the variability in methods used to assess miRNA expression creates challenges in comparing and/or synthesizing the literature, results to date suggest that the circulating form of several miRNAs known for playing a role in cancer (c-miR-133, c-miR-221/22, c-miR126 and c-let-7) are altered by both acute and chronic PA. Additional research should develop standardized procedures for assessing both c-miRNA and PA measurement to improve the comparability of research results regarding the direction and amplitude of changes in c-miRNAs in response to PA.
INTRODUCTION

MicroRNAs (miRNAs) are implicated in the etiology of various diseases, including cancer (1), and understanding their biologic characteristics has led to novel insights for cancer diagnosis, treatment and prognosis (2). MiRNAs are considered to be stable in healthy individuals, but external factors including lifestyle can impact their expression. Several studies have reported that physical activity (PA) can modulate miRNAs’ expression (3–5). The impact of PA on reducing cancer risk and improving cancer progression has been well documented, but the exact mechanisms underlying these relations are not yet completely understood (6,7). A better understanding of altered expression and function of miRNAs in response to various forms of PA could assist in clarifying the role of PA in cancer prevention and prognosis.

MiRNAs and cancer

MiRNAs are a class of small noncoding RNAs that regulate gene expression post-transcriptionally, either by mRNA cleavage, mRNA destabilization, or inhibition of translation (8). Since the first miRNA was discovered by Lee et. al. in 1993, more than 2500 human miRNA sequences have been identified (miRBase) (9). This rapid expansion of discovery can be partially explained by the broad importance of miRNAs in regular bodily functions. MiRNAs are predicted to modulate more than 60% of protein-coding genes (10) and are involved in numerous integral cellular processes, including development, proliferation, metabolism, and signal transduction (11,12). Given their regulatory importance, it is not surprising that miRNAs are widely implicated in carcinogenesis and progression. The mechanistic role of miRNAs in cancer was first discussed by Johnson et. al. in 2005 (13) and the number of studies has been rapidly expanding ever since. In both solid and hematological tumors, numerous miRNAs have been found to be altered, and their expression are associated with the severity and stage at diagnosis.
In breast cancer, for example, several miRNAs have been observed as very early biomarkers of this disease (15).

The role of miRNAs in carcinogenesis and cancer progression is twofold. Both in vivo and in vitro studies have demonstrated they target either tumor suppressors or oncogenes (16). Expression of particular miRNAs can downregulate various oncogenes or re-express tumor suppressor genes, leading to tumor suppression, whereas upregulation of other miRNAs, also referred to as oncomiRs, inhibits tumor suppressor genes or over-express oncogenes, thereby promoting tumor cell proliferation and metastasis (16).

MiRNAs are found in tissues and organs and are also released into the circulation in a remarkably stable form (17). The expression of those c-miRNAs has been found to be modified in numerous cancers including, but not limited to: colorectal, prostate, breast, hepatocellular, gastric and head and neck cancers (1,18–24). Altered c-miRNA expression was first observed in B-cell lymphoma patients by Lawrie et al. in 2008 (25) and it is now established that, on average, the expression of 100 c-miRNAs are altered in each cancer type. More importantly, the discovery of c-miRNAs in body fluids resulted in the implication of new possible pathways through which miRNAs may impact tumor development and progression, and led to novel insights for their use as therapeutic tools for cancer (27).

MiRNAs as potential mediators of the association between physical activity and cancer

PA has been shown to reduce cancer risk and progression (6,28–31). Multiple hypothesized biologic mechanisms have been proposed to explain these benefits (6,29,32) including reductions in chronic inflammation, regulation of metabolic factors, changes in insulin resistance, enhanced immune system function, and levels of circulating sex hormones, myokines or adipokines (6,29,32,33). The exact mechanisms, however, whereby PA alters cancer risk and
progression at various cancer sites are not fully understood and additional pathways are likely.

Since miRNAs are now well recognized for playing important roles in carcinogenesis and cancer outcomes, they could be involved in the PA-related benefits towards cancer.

The impact of PA on miRNAs has been investigated by several research groups, but mainly in the context of physical performance, muscle pathogenesis and muscular dysfunction related to aging, as well as in muscle disorders associated with diabetes, cancer and inflammation (3). The majority of the miRNAs shown to be altered by either acute or chronic exercise in these studies are muscle-specific miRNAs, also called myomiRs. MiRNAs are differentially expressed within various organs, and if a miRNA is expressed more than 20-fold in a specific tissue compared with the mean of its expression in other tissues, it is thus considered as a tissue-specific miRNA (34). The expression of a variety of miRNAs, and particular myomiRs, is modulated by PA within muscle tissues (4,35) as well as in plasma (5). Zacharewicz et. al. (4) have published a detailed review on miRNA expression within muscles in response to PA. Here we restrict our review to miRNA expression in blood following acute or chronic PA.

C-miRNAs are currently being extensively studied due to several advantages from a clinical and etiological perspective including a remarkable stability in the circulation, resistance to RNase activity (36), and preservation through multiple freeze-thaw cycles (37). Consequently, c-miRNAs can be easily evaluated by standard and relatively inexpensive qRT-PCR techniques, even in low concentrations (38), and their measurement is a non-invasive procedure (39). This is in stark contrast to the analysis of miRNA expression within specific tissues, which require biopsies. Based on these differences, c-miRNAs measured from stored blood samples will prove advantageous in the conduct of large epidemiological studies of PA-related cancer etiology. For these reasons, in this review we focused on the role of c-miRNAs as an underlying mechanism.
mediating PA’s benefits against cancer through the exploration of potential links between PA-induced c-miRNA modulation and cancer-related c-miRNA expression.

The majority of c-miRNAs are derived from leukocytes and endothelial cells (40) but they can also originate from organs exposed to high blood flow (3). When exercising, the blood flow is significantly elevated, with up to a 80-fold blood flow increase in times of high physical output (41,42), leading to expression changes in miRNAs originating from various organs (43–45), and in particular from skeletal muscles. The release of miRNAs in the blood circulation can originate from destroyed tissues (46,47), especially if the exercise load is great (48). However, increases in the expression of c-miRNAs have also been reported in the absence of cell damage markers in plasma (49). MiRNAs can, in fact, be exported by active transport systems, either encapsulated in extracellular vesicles (such as exosomes) (46,50,51), or associated with protein or lipid-based complexes (e.g., Argonaute2 \((\text{AGO}2)\), high density lipoproteins \((\text{HDL})\) and low density lipoproteins \((\text{LDL})\) (36,52–54). Importantly, increasing evidence shows that miRNAs, through their circulating form, can be transported from donor cells to recipient cells, where they exert their functions (18,54). C-miRNAs are thus being recognized as important components in intercellular communication (53,55,56), and have notably been demonstrated to play key roles in crucial cellular processes, such as apoptosis, proliferation, metastasis, and immunity (57,56). For example, exosomal-miR-105 secreted by breast cancer cells and transferred to endothelial cells have been shown to promote metastasis (58).
MATERIALS AND METHODS

We conducted a literature search up to March of 2016 in PubMed using the following search strategy: « miRNAs AND exercise » or « miRNAs AND physical activity » or « microRNAs AND exercise » or « microRNAs AND physical activity ». Only studies conducted in humans containing data measuring circulating miRNAs were included. We did not employ a minimum sample size threshold and studies with small numbers of participants were also included, as the total number of studies meeting our inclusion criteria was relatively small. Studies examining populations with disease were excluded, and all studies included in the review presented measurements among healthy subjects as underlying diseases may impact c-miRNAs.

To our knowledge, there are no data on the effect of PA on c-miRNA expression in cancer patients. One study has investigated the impact of PA on miRNA expression within tumor tissue based on an animal model, and is included in the discussion section. We also analyzed reference lists of the identified studies for additional relevant articles. The title and abstract were examined, and full text was obtained if the paper seemed eligible. No period or language restrictions were applied. We compiled the results from studies investigating c-miRNA expression in response to a single bout of PA (acute PA) in either normally active individuals (Table 1) or trained subjects (Table 2) as well as the impact of a training period and/or regular PA (chronic PA) on basal c-miRNA expression (Table 3).

Tables 1 and 2 include details on study (design, sample size, timing of blood draws), participant (age, gender, PA level) and protocol characteristics (training program if any, type of exercise (resistance or endurance exercise). Included in these tables are descriptions of the number of miRNAs screened, number of miRNAs altered by PA, miRNAs measured but not altered, and undetectable or unreliable miRNAs.
With regards to the type of exercise, we considered predominantly endurance exercises as exercises involving the whole body and increasing oxidative capacity and aerobic endurance (e.g. a marathon run), while resistance exercises were defined as exercises using machines, weights, or even individuals’ body weight to stimulate muscle hypertrophy and increase muscular strength or power (e.g. leg press, squats, pull-ups). We highlight the distinctions between normally active and “trained” participants, based on information provided by the studies. We considered the subjects trained if: 1) the subjects underwent a specific training program described in the study; 2) a large bout of exercise such as a marathon run was included in the protocol as undergoing such an effort implies previous training (even though not always specified in the reviewed studies); 3) the authors stated that the participants were “trained individuals” and/or part of a competitive program. We considered the subjects “untrained” or “normally active” if the participants engaged in recreational activity \( \leq 4 \) hours per week and/or if specified in the study.

In total, we included 5 studies examining normally active individuals and 10 studies investigating trained individuals, according to our criteria.

To facilitate comparisons across studies, we present the data for c-miRNAs that were examined in multiple studies. We first synthesize and discuss the results obtained for c-miRNA expression following acute PA, followed by a discussion and synthesis of results examining basal miRNA expression in response to chronic PA.

PA has also been shown to modulate miRNA expression within peripheral blood mononuclear cells (PBMCs). PBMCs are leukocytes with a round nucleus, and comprise lymphocytes (T cells, B cells, and natural killer cells), monocytes, and dendritic cells (59). Similar to c-miRNAs, PBMC miRNAs can easily be detected by standard RT-qPCR techniques, but it remains controversial whether their expression is similar or not to whole blood miRNAs (60,61). Thus, even though two different research groups found an impact of acute PA in
circulating leukocytes (62–65), those results are not discussed in this review.
RESULTS

We have identified a total number of 16 studies in our review, which are displayed in tables 1, 2 and 3. Among these studies, 14 investigated c-miRNA expression in response to a single bout of exercise (66–68,48,69,49,65,70–76), and six (49,66,71,75,77,78) evaluated the impact of chronic exercise on c-miRNA expression.

Impact of acute physical activity on c-miRNA expression

Acute PA refers to a single isolated PA session. It is clear that a single bout of PA alters expression of several c-miRNAs shortly after its completion (Table 1 and 2). However, the modalities of PA (frequency, intensity, timing and type (FITT)) and the individual’s physical fitness levels (trained or untrained) may impact those changes. Modifications in several c-miRNAs are not always observed immediately after PA, but are seen only after 2-3 hours of rest. For example, Banzet et al. reported no changes in miRNA expression immediately after the completion of a single bout of eccentric exercise (30 minutes downhill walking) but observed an increase in miR-1, miR-133a, miR-133b, miR-499-5p and miR-208b six hours post bouts of PA (68). These c-miRNAs then returned to baseline expression after periods of inactivity, which has been reported to be relatively slow in some studies (66–68,70,72). For example, decreased expression of c-miR-221 was still observed by Sawada et al. three days post-completion of a resistance exercise session (67).

Muscle- or cardiac-specific miRNAs

In healthy individuals, muscle- or cardiac specific miR-1, miR-133, miR-206, miR-499, miR-208 are expressed at low levels in the circulation, whereas miR-486 is generally found in higher concentrations (79,74). In response to PA, several studies have shown an increase in the circulating forms of miR-1, miR-133, miR-206, miR-208 and miR-499 immediately after the
completion of various PA modalities (FITT) (48,68,70,72,73,75,76), and a decrease in miR-486 (66). It can be noted that specific exercise modalities appear to impact changes in miRNA levels. Banzet et. al. found different c-miRNA expression patterns in normally active participants who underwent a downhill walk versus others who completed an uphill walk (68). Downhill walking is considered an eccentric exercise as the muscles actively lengthen during this effort, whereas uphill walking induces active shortening of the muscles and is thus considered a concentric exercise. Interestingly, Banzet et. al. found significantly higher muscle/cardiac specific c-miRNA expression for participants who walked downhill compared to subjects walking uphill (68). Thus, these data suggest that the type of muscle contraction involved in the exercises impacts c-miRNA expression. Furthermore, data from various studies also suggests that muscle/cardiac c-miRNAs can be differentially expressed depending on PA’s intensity. For example, when looking at c-miR-133, Uhlemann et. al. showed that modifications in c-miR-133 expression in response to PA were correlated with phosphocreatine kinase (CPK) activity, a marker for muscle damages: the more damaging the exercise was, the most altered c-miR-133 expression was (48).

Modulations in muscle/cardiac c-miRNA expression post-exercise appear to be temporary, yet the exact delay before a return to baseline values is unclear. When examining measures taken one day post-exercise, most studies showed that muscle and cardiac specific c-miRNAs had returned to their basal value. Others, however, reported a decrease in expression of those c-miRNAs compared to immediately after exercise, but still significantly elevated compared to baseline values. Focusing on c-miR-1 for example, four studies found similar expression of this c-miRNA between pre-exercise and 24 hours post exercise (49,68,75,76), while one other observed significantly higher expression compared to baseline value (but attenuated from expression measured immediately after exercise) (70).

Interestingly, high inter-individual variation in c-miR-499 expression has been reported in
response to an acute bout of endurance exercise in two different studies (68,72) which suggests that c-miR-499 is highly dependent on participants’ characteristics, notably their training status. MiR-499 is a cardiac-specific miRNA and studies have shown its circulating form may represent a marker of myocardial injury (80–84). Strenuous exercises such as marathon running can induce transient myocardial injuries (85–88), this risk being higher in less trained individuals (87,89). Therefore, the inter-individual variation observed in c-miR-499 expression following a marathon run may reflect variation in training among participants, and/or cardiac muscle exhaustion.

**Other circulating miRNAs**

Non muscle- or cardiac-specific c-miRNAs have also been reported to be impacted by acute PA, but the exact direction and magnitude of those changes remain unclear. Two different research groups observed an up-regulation of c-miR-126, an endothelial-specific miRNA involved in angiogenesis (90), immediately after a single bout of PA (48,72), while no statistical differences in c-miR-126 expression pre- and post-PA have also been reported (48,69). Interestingly, Uhlemann *et. al.* measured c-miR-126 expression before and after an acute bout of PA: subjects were either trained or untrained and the exercises which had to be completed varied among protocols in type, duration and intensity (48). They observed an upregulation in c-miR-126 in response to a single maximal symptom-limited test performed by healthy individuals, as well as in trained men who underwent four hours of bicycling at 70% of their anaerobic threshold, and in trained runners who completed a marathon. However, Uhlemann *et. al.* also reported no significant difference in c-miR-126 expression in trained subjects who performed a resistance training session compared to basal values (48). Since miR-126 is an endothelial-specific miRNA, the authors explained the increase in c-miR-126 expression following acute exercise observed in three of their protocols by exercise-induced endothelial damages, while they
suggested that the resistance exercise session, which resulted in unaltered c-miR-126 expression, did not cause such damages (48).

C-miR-146a, a miRNA known for playing a role in inflammation and immunity (91,92) has also been found to be altered by acute PA, however, the effects appear to be highly dependent on the type of activity intervention. Two studies have reported an up-regulation of this c-miRNA in response to a single bout of endurance exercise in trained individuals (49,72), but Nielsen et al. observed opposite results with a decrease in c-miR-146a in response to a similar type of PA in normally active subjects (71). In contrast, Van Craenenbroeck et al. reported no change in c-miR-146a expression in response to a single maximal symptom-limited test, while Sawada et al. measured no alteration in c-miR-146a expression in healthy men immediately after they performed resistance exercise session but found a decrease in its expression three days post-exercise (67). Interestingly, in trained athletes, Baggish et al. found an upregulation miR-146a in response to an acute bout of PA both before and after a training program, the magnitude of the elevation being higher after completion of the training program (93).

Similarly, changes in the circulating expression of miR-221 and miR-222, important players in vascular biology (94), have been reported, but high variations can be found between the studies (49,67,71). In response to a 60 min cycle ergometer exercise bout below anaerobic threshold, c-miR-221 has been found to be down-regulated in normally active participants by Nielsen et. al. (71), as opposed to Baggish et. al. who showed an up-regulation of c-miR-221 expression in trained individuals following an acute exhaustive cycling exercise (49). When assessing the impact of a short exhaustive bout of PA on those c-miRNA expression, Sawada et. al. did not report any changes immediately after PA completion, but found a decrease three days later (67). C-miR-222 expression in response to an acute bout of PA has only been investigated by two different studies: one of them showed an upregulation of this c-miRNA in trained men.
undergoing an exhaustive bout of exercise (49), while the other one reported no change in its expression between before and after a resistance exercise session (67). The differences observed between studies are likely attributable to differences in protocols, suggesting that alterations of c-miRNAs in response to acute PA are dependent on the dose and type of exercise (FIIT) as well as participants’ characteristics (e.g. age, gender, fitness level, health status, personal history, diet, smoking habits, etc).

**Impact of chronic physical activity on c-miRNA expression**

Chronic PA is defined as regular PA done over an extended time period (a minimum of several weeks). Interestingly, contrary to what is observed for c-miRNA expression following an acute bout of PA (Table 1 and 2), there is a general trend for a down-regulation of c-miRNAs expression in response to chronic PA (Table 3). Among the six different studies investigating the impact of chronic PA on resting expression of c-miRNAs we included in our review, four were intervention trials (49,66,71,75) and two were observational studies (77,78). The blood samples analyzed in those research projects were taken at rest, at least 12 hours after the last training session.

**Muscle- or cardiac-specific miRNAs**

Cardiac- or muscle specific c-miRNA expression changes in response to chronic PA are hard to measure because of their low concentrations in humans at rest, consequently, there are limited results thus far. For c-miR-1, one study reported no change between its resting expression before and after a 10-week marathon training period in either trained or untrained individuals (75), whereas two other research groups found its expression too low to interpret its measurement (66,78). A trend towards a decrease in c-miR-133 expression in response to a supervised training on a cycle ergometer was found by Nielsen et. al. (71), while other studies reported no changes.
(49,75) or non-detectable amounts for the quantification of c-miR-133 (66,78). Several studies measured the resting expression of c-miR-206 (66,78), c-miR-208 (66) and c-miR-499 (66,78) before and after a training period, but their expressions were too low to be interpreted. Finally, Aoi et al. found that a four week cycling program down-regulates c-miR-486 basal expression (66).

Other circulating miRNAs

When evaluating c-let-7d expression, a miRNA that has a crucial role in cell division and differentiation (95,96), Nielsen et al. showed a down-regulation of its baseline expression after a 12 week training period (71) while Bye et al.’s observational study (77) showed that subjects with high maximal oxygen uptake (VO_{2max}) (145.2±20.7 mL/kg^{0.75}/min) had a lower c-let-7d expression compared to individuals engaging in similar activity levels but with lower VO_{2max} (101.1±18.0 mL/kg^{0.75}/min).

For c-miR-21, Nielsen et al. reported that baseline expression was decreased after chronic PA (71), while the results obtained from Bye et al.’s observational study shows that independently of activity levels, individuals with high VO_{2max} have decreased c-miR-21 basal expression compared to subjects with lower VO_{2max} (77). However, Baggish et al. found an up-regulation of c-miR-21 after 13 weeks of rowing training, while Wardle et al. reported no alteration in expression between athletes (endurance or resistance trained) and controls, but showed a significant increase in resistance trained individuals when compared to endurance athletes (72,78).

C-miR-221 and c-miR-222 expression in response to chronic PA remains unclear. Baggish et al. reported increased expression of c-miR-222 after a 13-week training program (72), in line with Wardle et al.’s findings when comparing endurance trained athletes with control individuals (78). However, Wardle et al. found a down-regulation of c-miR-222 in
resistance trained athletes, and Bye et al.’s reported a decrease in c-miR-222 expression in individuals with high VO$_{2max}$ when compared to subjects with a lower VO$_{2max}$ (77,78). Similarly, various results have been found for the changes of c-miR-221 expression in response to chronic PA: Baggish et al. reported an increase in its baseline expression after a training period (72), whereas Wardle et al. found no statistical differences between trained athletes (endurance or resistance) and controls, but a down-regulation in resistance trained athletes when compared with endurance trained athletes (78).
DISCUSSION

Potential impact of PA-induced c-miRNA changes on cancer risk, progression, and treatment

Overall, the current results available from the scientific literature suggest that several c-miRNAs are impacted by acute PA (miR-1, miR-133, miR-206, miR-208, miR-499, miR-486, miR-126, miR-146, miR-221 and miR-222) and/or by chronic PA (miR-133, miR-486, let-7d, miR-21, miR-222, and miR-221). Importantly both acute PA and chronic PA appear to induce changes in c-miRNA expression depending on exercise modalities and individuals’ fitness status. While results to date are promising and suggest a clear impact of PA on miRNA expression, comparisons between studies are challenging and efforts should be devoted towards standardized protocols and procedures for miRNA collection, analysis and reporting.

The studies included in this review suggest that PA modulates c-miRNA expression in healthy individuals. Several studies have also observed that PA can alter c-miRNA expression within disease populations such as patients with chronic kidney diseases (69) and pre-diabetic individuals (97). To our knowledge, however, no data exists regarding the impact of PA on miRNA in cancer patients. PA also appears to be able to influence miRNA expression within organs other than skeletal muscles (98,99). Taken together, these elements suggest that PA may influence c-miRNA expression in cancer patients, perhaps via c-miRNA intercellular communication. This hypothesized mechanism is illustrated in Figure 1.

Throughout this section, we discuss how modulation of specific c-miRNA expression by PA might impact cancer risk, progression and treatments, and provide some examples of promising early findings. Figure 2 presents hypothesized examples of how PA could impact cancer via c-miRNA modulation using c-miR-133, c-miR-221/222, c-miR-126 and c-let-7.

Impact of miRNAs on cancer risk and development
Multiple miRNAs are involved in DNA repair, checkpoint functions, tumor suppression, etc. (100), and their modulation by PA might play an important role in cancer risk and progression. For example, PA can alter c-miR-133 expression (48,68,70–73,75,76,101), a well known myoMiR participating in myoblast differentiation which has also been identified as a tumor suppressor (102) in several cancers, including ovarian, colorectal, bladder, breast, prostate, and gastric cancers (101,103–108). MiR-133 has also been shown to be modified within muscle tissues in response to acute and chronic PA. More specifically, acute bouts of exercise seem to increase muscular miR-133 expression (109,110), while training tends to decrease expression (109,26). These data suggest that miR-133 can translocate from muscle tissue to blood vessels, and that this miRNA can impact cancer progression as depicted in Figure 1. Several studies suggest that miR-133 targets several oncogenes, such as the epidermal growth factor receptor (EGFR) (101) and the insulin-like growth factor 1 receptor (IGF1R) (108,111). When activated, those oncogenes stimulate various pathways causing deregulation in several cell processes, eventually leading to carcinogenesis. For example, activation of EGFR pathway leads to the stimulation of intracellular signaling cascades such as the mitogen-activated protein kinases/extracellular signal-regulated kinases (MAPK/ERK) pathway, which plays a role in cell cycle progression, differentiation, proliferation, and apoptosis (112,113). When activated, the EGFR pathways also stimulate the phosphoinositide 3-kinase - protein kinase B (PI3K/AKT) cascade, known for its crucial role in regulation of apoptosis and protein synthesis (114,115). An increase in c-miR-133 by PA originating from muscle tissue, may therefore impact tumor cells and regulate target oncogenes and associated pathways.

Similarly, let-7 is a tumor suppressor and pro-apoptotic miRNA (116) whose expression is decreased in numerous cancers (117), and reported to be modulated in plasma by exercise (71,77). While no direct evidence was identified in humans, in an animal model, breast tumor-
bearing mice who underwent five weeks of interval exercise training (treadmill running) had increased let-7 expression within the tumor itself when compared to breast-tumor sedentary mice (118). Let-7 is known for inhibiting mRNA translation of well-known oncogenes, including the RAS family (HRAS, KRAS, and NRAS) (13) and c-MYC (119) (120). When activated, Ras stimulates several signaling pathways, including MAPK cascade and PI3K/AKT (121), thereby influencing many cellular functions.

We must note the complex and often paradoxical role of miRNAs, with several miRNAs exerting stimulatory as well as inhibitory effects depending on cancer type or stage of the disease (122–124). MiR-221 and miR-222 for example have a dual role: they can either act as tumor suppressors or oncogenes. On one hand, miR-221 and miR-222 have been found to relent cancer progression in several cancer types, and their expression in the circulation have been found to be altered by PA in several studies (49,71,72,77,78). In gastrointestinal stromal tumors for example, miR-221 and miR-222 are thought to have prophylactic effects by negatively regulating the stem cell factor receptor KIT, and are found under-expressed in tumors when compared to healthy tissues (125–127). KIT is a receptor tyrosine-kinase (RTK), and its activation leads to the stimulation of several intracellular signaling pathways, including the signal transducer and activator of transcription 3 (STAT3), PI3K, phospholipase C (PLC), and the MAPK cascade (128–130). KIT promotes cell survival, proliferation and motility (131), and its inhibition by miR-221 and miR-222 therefore contributes to carcinogenesis suppression. Modulation of those miRNAs by PA could thereby inhibit KIT activation, consequently lowering the risk of developing cancer.

On the other hand, miR-222 and miR-221 have been shown to act as oncomiRs in other cancer types. In lung and liver cancer for example, these miRNAs have been shown to inhibit the action of the phosphatase and tensin homolog (PTEN), known to inhibit MAPK/ERK pathway, and the tissue inhibitor of metalloproteinases-3 (TIMP3), thereby enhancing cell proliferation and...
migration through \textit{PI3K/AKT} pathway (132). The dual role played by miR-222 and miR-221 suggest that clarifying the influence of exercise modalities (endurance vs resistance, short vs long duration, regular vs irregular training, etc.), tissue and/or cancer site of interest will be extremely important in subsequent research.

\textbf{Impact of miRNAs on cancer invasion and metastasis}

PA also modulates c-miRNAs involved in cell proliferation, invasion and metastasis (Figure 2). For example miR-21 is altered by resistance and endurance training (71,72,78) and is also known for participating in tumor invasion. In fact, \textit{in vitro} studies have shown that in several cancer types, miR-21 knock-down mice displayed suppression of cell proliferation and tumor growth (133), as well as reduced invasion and metastasis (133–135). Furthermore miR-21 negatively regulates tumor suppressor programmed cell death 4 (\textit{PDCD4}) (136) and downstream signaling targets (137,138) in colorectal cell lines. The results in this review (Tables 1, 2 and 3) suggest that acute exercise can transiently upregulate c-miR-21 expression (65,93), while chronic exercise (which reflects physiological adaptations) can also lead to alterations in miR-21 expression within circulation (71,77), however, the influence of chronic PA is less clear. By lowering miR-21 expression within cancer cells, PA may restore \textit{PDCD4} and \textit{PTEN} activation and limit cancer proliferation. This is supported by literature that suggests PA is able to modulate miR-21 within multiple tissues/fluids, for example muscle tissue in mice (139) as well as in plasma in healthy human subjects (93,65,71,77,78), as well as in tumors of breast tumor-bearing mice (118) (Figure 1).

The up-regulation of c-miR-126 by acute PA (48,72) might also represent a pathway through which PA impacts cancer progression. In breast cancer, miR-126 regulates the tumor microenvironment composition by directly inhibiting stromal cell-derived factor-1 alpha (\textit{CXCL12}) expression and indirectly suppressing chemokine ligand 2 (\textit{CCL2}) expression in
cancer cells (140). These two chemokines play a role in recruiting stromal cells to the primary
tumor microenvironment (141,142), thereby leading to cancer cell invasion and metastasis.
Therefore, the increase in c-miR-126 expression in response to acute PA followed by active
transport into tumor cells could lead to inhibition of CXCL12 and CCL2, consequently
suppressing cancer expansion by modifying the tumor microenvironment composition (48).

Overall, PA-induced c-miRNA expression changes could have the potential to impact
tumorigenesis and cancer development. Importantly, several studies suggest that re-expression of
tumor-suppressor miRNAs within tumor tissues can inhibit tumor growth, thereby representing a
promising therapeutic tool against cancer (18,143–145). For example, re-expression of let-7
within various tumor types have been proven to slow cancer growth (95,146–148) and is thus
considered a promising tool against cancers under-expressing let-7 family members (146,149).
Additional research, particularly large intervention studies in populations of cancer patients are
needed to determine the exact impact of PA on miRNA expression and potential roles in cancer
therapy.

Limitations of the research to date

Investigating c-miRNAs in response to PA presents several challenges. First, to date,
there are few studies that have compared similar c-miRNAs using comparable methods to enable
direct comparisons across studies. Although some consistency has been observed for several c-
miRNAs such as miR-133 (48,70,72,73,75,76), contradictory results have often been observed.
This inconsistency can largely be attributed to discrepancy in methods across studies, including:
1) differences in sample collection; 2) post-processing of samples and; 3) the use of serum or
plasma for miRNAs’ extraction.

Different normalization strategies have been used between the reviewed studies. The
current results available on c-miRNA expression changes in response to PA should therefore be carefully interpreted. For example, Nielsen et. al. used a stable expressed c-miRNA to account for the biological variation between samples, whereas Baggish et. al. used a synthetic spike in approach (71,72). Some studies also included a hemolysis control phase in the study design, since it has been shown that hemolysis occurring during blood collection has substantial impact on the miRNA content in plasma/serum (150). This issue occurs because erythrocytes contain numerous miRNAs that unavoidably will contaminate a plasma sample if the erythrocyte bursts during sampling (151).

Another methodologic factor likely to impact the reliability of the results obtained from the various studies reviewed here is the fact that miRNA concentrations vary between serum and corresponding plasma samples (152). Analyzing and comparing miRNA expression from serum and plasma within or between studies should be done carefully.

To date, miRNA expression in response to PA has mainly been measured in the circulation and in muscles, but it would also be interesting to study the changes in miRNA expression in other tissues. More specifically, investigating miRNA expression after PA in target tissues, and more specifically tumor tissues, would provide novel data of how PA can impact cancer through miRNA modulation. Tissue-specific approaches would also aid in a better understanding of the role of c-miRNAs in specific cancer sites that may result in the development of targeted novel therapies.
CONCLUSIONS AND FUTURE DIRECTIONS

PA represents a lifestyle behaviour that influences the expression of several c-miRNAs, some of which have been associated with carcinogenesis and cancer progression. Our results suggest that alteration of miRNAs within the circulation is dependent on the type/modality/frequency of exercise as well as on the participants characteristics. Furthermore, the evidence to date on c-miRNA expression in response to PA is limited by small sample sizes without standardized measures of miRNA or physical activity. miRNAs appear to have a meaningful impact on cancer risk and progression, however, the effect vary between cancer types. Therefore, it appears essential to provide a better understanding of how various types of PA in a specific population could impact c-miRNA expression: it could represent a useful tool for healthcare practitioners in establishing and monitoring PA programs for cancer patients.

Future research should focus on large epidemiologic studies with standardized blood storage and collection as well as standardized measures of c-miRNA expression and objective measures of PA. Additional consistency is needed to provide more meaningful conclusions as well as standardization of PA measurement. Further investigation into the effects of PA on miRNAs is necessary and could have implication both for cancer prevention, treatment and survival outcomes.
REFERENCES


120. Dang CV. MYC, Metabolism, Cell Growth, and Tumorigenesis. Cold Spring Harb Perspect Med [Internet]. 2013;3. Available from:
http://perspectivesinmedicine.cshlp.org/content/3/8/a014217.abstract


<table>
<thead>
<tr>
<th>Reference</th>
<th>Subjects</th>
<th>Type of acute PA</th>
<th>Plasma/serum base</th>
<th>No of miRNAs screened</th>
<th>MiRNAs altered by PA (compared to basal values)</th>
<th>Unaltered miRNAs among the measured ones</th>
<th>miRNAs not detectable or unreliable</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Acute endurance exercise</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aoi et al., 2013 (66)</td>
<td>10 males 21.5±4.5 yrs</td>
<td>60min cycling exercise (70% VO₂max)</td>
<td>Serum</td>
<td>-</td>
<td>miR-486↓</td>
<td>NONE</td>
<td>miR-1, miR-133a, miR-206, miR-208b, miR-499</td>
</tr>
<tr>
<td>Banzet et al., 2013(68)</td>
<td>9 males 27 to 36 yrs</td>
<td>30min uphill walking exercise (concentric)</td>
<td>Plasma</td>
<td>-</td>
<td>miR-181b↑, miR-214↑, miR-499-5p↑</td>
<td>Post 2h and 6h: miR-1↑, miR-208b↑</td>
<td>miR-181a, miR-206, miR-208a</td>
</tr>
<tr>
<td>Banzet et al., 2013 (68)</td>
<td>9 males 27 to 36 yrs</td>
<td>30min downhill walking exercise (eccentric)</td>
<td>Plasma</td>
<td>-</td>
<td>NONE</td>
<td>Post 2h, 6h, and 1 day: miR-499-5p↑</td>
<td>miR-181a, miR-206, miR-208a</td>
</tr>
<tr>
<td>Uhlemann et al., 2014 (48)</td>
<td>7 males and 6 females 30.4±2.0 yrs</td>
<td>Maximal cycle ergometry test</td>
<td>Plasma</td>
<td>-</td>
<td>miRNA-126↑</td>
<td>No recovery blood draw time points</td>
<td>miR-133</td>
</tr>
<tr>
<td>Van Craenenbroeck et al., 2015 (69)</td>
<td>7 males and 5 females 43.4±4.7 yrs</td>
<td>Maximal cycle ergometry test</td>
<td>Plasma</td>
<td>-</td>
<td>miR-150↑</td>
<td>No recovery blood draw time points</td>
<td>miR-146a, miR-206, miR-120, miR-21</td>
</tr>
<tr>
<td><strong>Acute resistance exercise</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sawada et al., 2013 (67)</td>
<td>3 males 29.9±1.2 yrs</td>
<td>Bench press and leg press (5 sets of 10 reps with 1min rest between sets)</td>
<td>Serum</td>
<td>1458</td>
<td>NONE</td>
<td>Post 1 day: miR-149*↑</td>
<td>miR-20a, miR-222</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Post 3 days: miR-146a↓, miR-221↓</td>
<td>miR-21, miR-328, miR-1908, miR-299-5p</td>
</tr>
</tbody>
</table>
*Results of a systematic review of studies investigating the impact of acute PA on c-miRNA expression in healthy and “normal” activity levels humans subjects either immediately after acute exercise completion and/or several hours up to a couple days after.
Abbrevations: ex: exercise; wk: week; yrs: years.
## Table 2: Effect of acute physical activity on the expression of c-miRNAs at various time points in healthy trained subjects

<table>
<thead>
<tr>
<th>Reference</th>
<th>Subjects</th>
<th>Training program</th>
<th>Type of acute PA</th>
<th>Plasma/ Serum base</th>
<th>No of miRNAs screened</th>
<th>MiRNAs altered by PA (compared to basal values)</th>
<th>Unaltered miRNAs among the measured ones</th>
<th>MIRNAs not detectable or unreliable</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baggish et. al., 2011 (49)</td>
<td>10 males 19.1±0.6 yrs</td>
<td>13 weeks rowing training</td>
<td>Maximal cycle ergometry test</td>
<td>Plasma</td>
<td>-</td>
<td>miR-146a↑, miR-21↑, miR-222↑, miR-221↑</td>
<td>No recovery blood draw time points</td>
<td>miR-20a, miR-210, miR-328, miR-133a</td>
</tr>
<tr>
<td>Tonevitsky et. al., 2013 (65)</td>
<td>8 males 21.7±2.6 yrs</td>
<td>Regular ski training</td>
<td>30min run on a treadmill (80% VO2 max)</td>
<td>Serum</td>
<td>200</td>
<td>miR-24-2-5p↑, miR-27a-5p↑, miR-181a-5p↑</td>
<td>Post 1/2h and post 1h: miR-24-2p↓, miR-27a-5p↓, miR-181-5p↓</td>
<td>miR-21-5p↑</td>
</tr>
<tr>
<td>Mooren et. al., 2014 (70)</td>
<td>14 males 42.8±6.0 yrs</td>
<td>Regular endurance training</td>
<td>Marathon run</td>
<td>Plasma</td>
<td>-</td>
<td>miR-1↑, miR-133a↑, miR-206↑, miR-499↑</td>
<td>Post 1 day: miR-1↑, miR-133a↑</td>
<td>miR-206↑, miR-21</td>
</tr>
<tr>
<td>Nielsen et. al., 2014 (71)</td>
<td>13 males 28±8 yrs</td>
<td>12 weeks endurance training (cycle ergometry)</td>
<td>60min cycle ergometry exercise (65% Pmax)</td>
<td>Plasma</td>
<td>188</td>
<td>miR-221↓, miR-30b↓, miR-106a↓, miR-146a↓, miR-151-3p↓, miR-151-5p↓</td>
<td>Post 1h: miR-338-3p↑, miR-143↑, miR-330-3p↑, miR-145↑↑, miR-223↑, miR-424↑↑, miR-139-5p↑</td>
<td>miR-133b↑↑</td>
</tr>
<tr>
<td>Baggish et. al., 2014 (72)</td>
<td>21 males 51.8±1.4 yrs</td>
<td>Regular endurance training</td>
<td>Marathon run</td>
<td>Plasma</td>
<td>-</td>
<td>miR-126↑, miR-1↑, miR-133a↑, miR-134↑, miR-146a↑</td>
<td>Post 1 day: miR-499-5p↑</td>
<td>miR-133a↑↑</td>
</tr>
<tr>
<td>Uhlemann et. al., 2014 (48)</td>
<td>13 males 32.4±2.3 yrs</td>
<td>Regular endurance training</td>
<td>4h cycle ergometry exercise (70% anaerobic threshold)</td>
<td>Plasma</td>
<td>-</td>
<td>miR-126↑</td>
<td>Post 1h: NONE</td>
<td>miR-133</td>
</tr>
<tr>
<td>Uhlemann et. al., 2014</td>
<td>22 males 56.8±5.2 yrs</td>
<td>Regular endurance</td>
<td>Marathon run</td>
<td>Plasma</td>
<td>-</td>
<td>miR-126↑</td>
<td>No recovery blood draw time points</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Gender</td>
<td>Range</td>
<td>Training Type</td>
<td>Exercise Protocol</td>
<td>miRNA Changes</td>
<td>Recovery Blood Draw Time Points</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------</td>
<td>-------</td>
<td>--------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gomes et al., 2014 (73)</td>
<td>5 males</td>
<td>31.6±4.39 yrs</td>
<td>Regular endurance training</td>
<td>Half-marathon run</td>
<td>Plasma miR-1† miR-133a† miR-206†</td>
<td>No recovery blood draw time points</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cui et al., 2015 (74)</td>
<td>18 males</td>
<td>20.23±0.9 7 yrs</td>
<td>Regular exercise training (activity type not specified)</td>
<td>Cycle ergometry sprint intervals (2 sets of 30s all out sprints with 4min rest between sets)</td>
<td>Plasma miR-1↓ miR-133a↓ miR-133b↓ miR-122↓ miR-16↓</td>
<td>No recovery blood draw time points miR-206 miR-499</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clauss et al., 2016 (75)</td>
<td>15 males</td>
<td>40.1±1.4 yrs</td>
<td>Marathon training ≤40km/wk for 10 wk</td>
<td>Marathon run</td>
<td>Plasma miR-1† miR-133a†</td>
<td>Post 1 day: miR-133a† miR-30a miR-26a miR-29b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clauss et al., 2016 (75)</td>
<td>15 males</td>
<td>40.0±1.7 yrs</td>
<td>Marathon training ≥55km/wk for 10 wk</td>
<td>Marathon run</td>
<td>Plasma miR-1† miR-133a† miR-30a†</td>
<td>Post 1 day: NONE miR-26a miR-29b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Min et al., 2016 (76)</td>
<td>20 males and 8 females</td>
<td>53.0±6.5 yrs</td>
<td>Regular endurance training</td>
<td>Marathon run</td>
<td>Plasma miR-1† miR-133a† miR-206†</td>
<td>Post 1 day: miR-499-5p†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uhlemann et al., 2014 (48)</td>
<td>4 males and 7 females</td>
<td>37±2 yrs</td>
<td>Non-supervised regular training (activity type not specified)</td>
<td>Lat pulldown, leg press and butterfly (3 sets of 15 reps with 1min rest between sets)</td>
<td>Plasma miR-133†</td>
<td>Post 1h: NONE miR-126</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Legend: † is placed after borderline significant miRNAs

*Results of a systematic review of studies investigating the impact of acute PA on c-miRNA expression in healthy trained human subjects either immediately after acute exercise completion and/or several hours up to a couple days after.

Abbreviations: No: number; ex: exercise; reps: repetitions; wk: week; yrs: years.
Table 3: Effect of chronic/regular/long-term physical activity on c-miRNA levels in healthy subjects

<table>
<thead>
<tr>
<th>Reference</th>
<th>Type of study</th>
<th>Participants characteristics</th>
<th>Training program</th>
<th>Blood draw timing &amp; plasma base</th>
<th>No of miRNAs screened</th>
<th>MiRNAs altered by chronic PA</th>
<th>miRNAs measured but not altered by chronic PA</th>
<th>miRNAs not detectable/unreliable</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chronic endurance exercise</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baggish <em>et. al.</em>, 2011 (49)</td>
<td>Intervention</td>
<td>10 males 19.1±0.6 yrs</td>
<td>13 weeks rowing training</td>
<td>At least 12h post exercise -plasma</td>
<td>-</td>
<td>miR-146a↑</td>
<td>miR-221↑</td>
<td>miR-328 miR-210</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Very trained</td>
<td></td>
<td></td>
<td></td>
<td>miR-222↑</td>
<td>miR-20a↑</td>
<td>miR-133a</td>
</tr>
<tr>
<td>Aoi <em>et. al.</em>, 2013 (66)</td>
<td>Intervention</td>
<td>10 males 21.5±4.5 yrs</td>
<td>4 weeks cycling training</td>
<td>2 days post training period -serum</td>
<td>-</td>
<td>miR-486↓</td>
<td></td>
<td>miR-1 miR-133a miR-133b miR-208b miR-206 miR-208b miR-499</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Normally active</td>
<td></td>
<td></td>
<td></td>
<td>miR-342-3p↓</td>
<td>miR-185↓</td>
<td>miR-148b↓‡ miR-133a↓‡ miR-92a↓‡ miR-29b↓‡</td>
</tr>
<tr>
<td>Nielsen <em>et. al.</em>, 2014 (71)</td>
<td>Intervention</td>
<td>7 males 28±5 yrs</td>
<td>12 weeks of supervised training on cycle ergometer</td>
<td>3 days and 5 days post training period -plasma</td>
<td>188</td>
<td>miR-25↓</td>
<td></td>
<td>miR-16-2 miR-20a-1 miR-103a miR-192 miR-451 miR-21 miR-146a miR-221 miR-133a miR-206 miR-499</td>
</tr>
<tr>
<td>Wardle <em>et. al.</em>, 2015 (78)</td>
<td>Observational</td>
<td>20 males 22.6±3.7 yrs</td>
<td>Trained: 13h of training per week</td>
<td>At least 12h post PA -plasma</td>
<td>-</td>
<td>miR-222↑</td>
<td></td>
<td>miR-1 miR-133a miR-26a miR-29b</td>
</tr>
<tr>
<td>Clauss <em>et. al.</em>, 2016 (75)</td>
<td>Intervention</td>
<td>15 males 40.1±1.4 yrs</td>
<td>Marathon training: Running of ≤40km/week for 10 weeks</td>
<td>After the training period -plasma</td>
<td>-</td>
<td>NONE</td>
<td></td>
<td>miR-1 miR-133a miR-26a miR-29b</td>
</tr>
<tr>
<td>Clauss <em>et. al.</em>, 2016 (75)</td>
<td>Intervention</td>
<td>15 males 40.0±1.7 yrs</td>
<td>Marathon training: Running of ≥55km/week for 10 weeks</td>
<td>After the training period -plasma</td>
<td>-</td>
<td>NONE</td>
<td></td>
<td>miR-1 miR-133a miR-26a miR-29b</td>
</tr>
</tbody>
</table>

**Chronic resistance exercise**


<table>
<thead>
<tr>
<th>Wardle et al., 2015 (78)</th>
<th>Observational</th>
<th>20 males 22.2±2.1 yrs Trained (resistance athletes) vs Control (not active)</th>
<th>Trained: 13h of training per week</th>
<th>At least 12h post PA -plasma</th>
<th>miR-222↓</th>
<th>miR-16-2</th>
<th>miR-20a-1</th>
<th>miR-21</th>
<th>miR-133a</th>
<th>miR-206</th>
<th>miR-499</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Unspecified chronic exercise (endurance and/or resistance exercise)

| Bye et al., 2013 (77) | Observational | MiRNA screening: 12 males 12 and females 40-45 yrs | Training included in lifestyle | Before the start of the exercise test measuring the subjects' VO2max -serum | 720    | Screening: Males and females: miR-210↓ miR-125a↓ miR-652↑ Males only: miR-151↑ miR-29a↓ let-7d↓ Women only: miR-210↓ miR-125a↓ miR-21↓ Validation cohort: Males and females: miR-222↓ miR-210↓ Males only: miR-21↓ |
|------------------------|--------------|-------------------------------------------------|-------------------------------|---------------------------------|--------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|                        |              |                                                 |                               |                                 |        |                     |                     |                     |                     |                     |                     |

Legend: ‡ is placed after borderline significant miRNAs

*Results of a literature review of intervention and observational studies investigating the impact of chronic PA on c-miRNA expression in humans.

Abbrevations: No: number; yrs: years.
Figure Legend

Figure 1: Hypothesized pathways of miRNA transport from muscles to tumor cells via the circulation. MiRNAs can be exported from one cell to another via plasma through various active transport systems including: exosomes developed within multivesicular bodies (MVBs); released into the blood circulation after fusion of the MVBs with the plasma membrane; transport through protein or lipid-based complexes, such as HDL, and delivered to recipient cells.

Abbreviations: MVB: Multi-Vesicular Body.

Figure 2: Hypothesized mechanisms of action of physical activity on cancer risk and progression through c-miRNA modulation. Multiple c-miRNAs (MiR-126, MiR-221/222, Mir-133 and Let-7) which impact pathways involved in cancer risk and progression have been shown to be altered by physical activity.